title: Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
abstract: Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.
authors.affiliation: Division of Hematology-Oncology, the University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Voorhees
authors.affiliation: Department of Lymphoma/Myeloma, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Robert Z
authors.initials: RZ
authors.lastname: Orlowski
authors.affiliation: Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA.
authors.forename: Flora
authors.initials: F
authors.lastname: Mulkey
authors.affiliation: Department of Oncology, Kinston Medical Specialists, P.A., Kinston, NC, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Watson
authors.affiliation: Health Informatics Institute, University of South Florida, Tampa, FL, USA.
authors.forename: Susan
authors.initials: S
authors.lastname: Geyer
authors.affiliation: Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA.
authors.forename: Ben L
authors.initials: BL
authors.lastname: Sanford
authors.affiliation: Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Bennett
authors.affiliation: Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Asher A
authors.initials: AA
authors.lastname: Chanan-Khan
authors.affiliation: Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
authors.affiliation: Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000069286:Bortezomib / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate; D013997:Time Factors
chemical_list: C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D000069286:Bortezomib; D004317:Doxorubicin
keywords: anthracyclines; international staging system; multiple myeloma; proteasome inhibitors